Paper24893003
Phage neutralization by sera of patients receiving phage therapy.
Łusiak-Szelachowska M and 11 others. Viral Immunol, 2014. Cited by 173 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Phage neutralization by sera of patients receiving phage therapy. Papers, record 24893003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24893003
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Viral | Major topic |
| Bacterial Infections | Major topic |
| Bacteriophages | Major topic |
| Case-Control Studies | |
| Enzyme-Linked Immunosorbent Assay | |
| Humans | |
| Neutralization Tests | |
| Virus Inactivation |
Source PubMed
References9
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19,066,828 | Preparation and characterization of anti-phage serum. | Methods Mol Biol | 2009 | https://conductscience.org/library/papers/19066828 | PubMed |
| 2 | 4,273,800 | Antibodies against staphylococcal bacteriophages in human sera. I. Assay of antibodies in healthy individuals and in patients with staphylococcal infections. | Acta Pathol Microbiol Scand B Microbiol Immunol | 1973 | https://conductscience.org/library/papers/4273800 | PubMed |
| 3 | 3,455,646 | Immunogenic effect of bacteriophage in patients subjected to phage therapy. | Arch Immunol Ther Exp (Warsz) | 1987 | https://conductscience.org/library/papers/3455646 | PubMed |
| 4 | 15,980,363 | Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/15980363 | PubMed |
| 5 | 22,748,808 | Phage as a modulator of immune responses: practical implications for phage therapy. | Adv Virus Res | 2012 | https://conductscience.org/library/papers/22748808 | PubMed |
| 6 | 4,273,801 | Antibodies against staphylococcal bacteriophages in human sera. II. Assay of antibodies in exacerbation and regression of chronic staphylococcal osteomyelitis. | Acta Pathol Microbiol Scand B Microbiol Immunol | 1973 | https://conductscience.org/library/papers/4273801 | PubMed |
| 7 | 5,416,642 | The serum antibody response to bacteriophage phi chi 174 in germ-free and conventionally reared mice. II. Kinetics of the serum antibody response following primary immunization. | Immunology | 1970 | https://conductscience.org/library/papers/5416642 | PubMed |
| 8 | 21,908,031 | Effect of rituximab on human in vivo antibody immune responses. | J Allergy Clin Immunol | 2011 | https://conductscience.org/library/papers/21908031 | PubMed |
| 9 | 22,748,809 | Clinical aspects of phage therapy. | Adv Virus Res | 2012 | https://conductscience.org/library/papers/22748809 | PubMed |
Cited by129
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 173 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,979,208 | Phage therapy against Pseudomonas aeruginosa biofilm infections: challenges and advanced strategies. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42979208 | PubMed |
| 42,938,771 | Novel Therapeutic Strategies for Preventing Recurrent Urinary Tract Infections in Women: A Narrative Review. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42938771 | PubMed |
| 42,614,511 | Assessment of water prophylaxis and biosafety in finfish aquaculture - current and emerging technologies. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42614511 | PubMed |
| 42,597,638 | Harnessing phages in the age of antibiotic resistance: immunological perspectives. | Front Immunol | 2026 | https://conductscience.org/library/papers/42597638 | PubMed |
| 42,491,532 | Bacteriophage therapy for controlling poultry production problems. | Iran J Vet Res | 2025 | https://conductscience.org/library/papers/42491532 | PubMed |
| 42,436,825 | Mechanisms of Resistance, Insights From Case Reports, and Future Prospects in Mycobacteriophage Therapy. | J R Soc N Z | 2026 | https://conductscience.org/library/papers/42436825 | PubMed |
| 42,367,797 | Innate immune recognition and immunomodulatory effects of bacteriophages: implications for phage therapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42367797 | PubMed |
| 42,263,718 | Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime-zidebactam alongside phage therapy in the USA. | Lancet Infect Dis | 2026 | https://conductscience.org/library/papers/42263718 | PubMed |
| 42,231,337 | Antibacterial potential of five phages in controlling Enterococcus faecalis and Enterococcus faecium. | Virol J | 2026 | https://conductscience.org/library/papers/42231337 | PubMed |
| 42,146,041 | A review on phytochemical and bacteriophage based therapeutic strategies for the management of Brucellosis. | Front Vet Sci | 2026 | https://conductscience.org/library/papers/42146041 | PubMed |
| 42,032,071 | Cross-reactive anti-prophage antibodies and bacterial heteroresistance implicated in phage therapeutic failure. | Nat Med | 2026 | https://conductscience.org/library/papers/42032071 | PubMed |
| 41,946,778 | Assessing the impact of phage therapy on growth performance, microbiome and phage specific immune response in chickens. | Sci Rep | 2026 | https://conductscience.org/library/papers/41946778 | PubMed |
| 41,892,478 | Bacteriophage Therapy Against Shigella spp.: A Precision Antimicrobial Strategy. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/41892478 | PubMed |
| 41,853,532 | Bacteriophages: a double-edged sword in the gastrointestinal tract. | Front Microbiomes | 2024 | https://conductscience.org/library/papers/41853532 | PubMed |
| 41,750,453 | Bacteriophage-Based Control of Methicillin-Resistant Staphylococcus aureus: Anti-Biofilm Activity, Surface-Active Formulation Compatibility, and Genomic Context. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/41750453 | PubMed |
| 41,516,055 | Analysis of Pro- and Anti-Inflammatory Gene Response Patterns in Patients Receiving Phage Therapy. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41516055 | PubMed |
| 41,065,359 | In vitro activity of antibiotic monotherapy and combination therapy with bacteriophages against Staphylococcus aureus LVAD-driveline infections. | J Clin Microbiol | 2025 | https://conductscience.org/library/papers/41065359 | PubMed |
| 40,358,692 | Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead. | Int Urogynecol J | 2025 | https://conductscience.org/library/papers/40358692 | PubMed |
| 39,866,829 | Phage therapy in the management of respiratory and pulmonary infections: a systematic review. | Ther Adv Infect Dis | 2025 | https://conductscience.org/library/papers/39866829 | PubMed |
| 39,861,891 | Selected Mechanisms of Action of Bacteriophages in Bacterial Infections in Animals. | Viruses | 2025 | https://conductscience.org/library/papers/39861891 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24893003
GET https://conductscience.org/api/papers/v1/24893003/cited_by?page=2